leisure time -WSS

leisure time

author：hotspot 2025-09-06 02:13:46 - browse：3428

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

WSS

Mitch McConnell episode has important public health takeaway

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Why Charlie Gard's case is so disturbing to Americans

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Sage hopes for a blockbuster in antidepressant now before FDA

hotspot

leisure time

entertainment

Drug repurposing or repositioning? The language matters

Trump indictment: Who are the 'co

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Anesthesiologist group: stop taking Ozempic before surgery

Colorectal cancer study finds potential in overlooked immune cell

How to save PrEP access — and even expand it

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

United colonoscopy coverage change 'may cost lives,' doctors say

VC firm General Catalyst wants to buy a health system

Wikipedia

Mega Millions pot grows to $1.25 billion after no winner

Mitch McConnell episode has important public health takeaway

Trump indictment: Who are the 'co

Why age limits for politicians are a terrible idea

Why age limits for politicians are a terrible idea

EQRx, failed developer of low

knowledge

explore

explore

hotspot